A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Randomized comparison data on the efficacy and safety of deferasirox for myocardial iron removal in transfusion dependent patients are lacking. CORDELIA was a prospective, randomized comparison of deferasirox (target dose 40 mg/kg per day) vs subcutaneous deferoxamine (50-60 mg/kg per day for 5-7 da...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Pennell, Dudley J., Porter, John B., Piga, Antonio, Lai, Yongrong, El-Beshlawy, Amal, Belhoul, Khawla M., Elalfy, Mohsen, Yesilipek, Akif, Kilinç, Yurdanur, Lawniczek, Tomasz, Habr, Dany, Weisskopf, Marianne, Zhang, Yiyun, Aydinok, Yesim
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2014
Teme:
Plenary Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3945858/
https://ncbi.nlm.nih.gov/pubmed/24385534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-04-497842
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki